Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
November 16 2020 - 5:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
SEC File Number
000-55331
NOTIFICATION OF LATE FILING
(Check
One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form
10-D ☐ Form N-SAR ☐ Form N-CSR
For Period Ended: September 30,
2020
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR
For the Transition Period Ended: ________________________
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein.
If the
notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Inspyr
Therapeutics, Inc.
Full Name
of Registrant
GenSpera,
Inc.
Former
Name if Applicable
2629 Townsgate
Road #215
Address
of Principal Executive Office (Street and Number)
Westlake
Village, CA 91361
City,
State and Zip Code
PART
II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III-- NARRATIVE
State below in reasonable detail why the Form 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach
extra sheets if needed.)
The compilation, dissemination and review
of the information required to be presented in the Form 10-Q for the period ending September 30, 2020 could not be completed and
filed by November 16, 2020, without undue hardship and expense to the registrant. The registrant anticipates that it will file
its Form 10-Q for the period ended September 30, 2020 within the “grace” period provided by Securities Exchange Act Rule
12b-25.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification
Michael Cain
|
|
(818)
|
|
597-7552
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
☐ Yes ☒ No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Inspyr Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
Date November 16, 2020
|
By
|
/s/ Michael Cain
|
|
|
Michael Cain
Chief Executive Officer
|
3